UNSPSC 51112036: Alectinib

Alectinib is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC).

UNSPSC 51112036 Alectinib, a Commodity code, shows no meaningful recent state and local procurement activity. The recent-opportunities block contains one record explicitly tagged with this code—a notice of the Williamson County Purchasing Department's office relocation—which the source itself identifies as nonprocurement administrative communication with no scope, deliverables, timeline, or contract value. The remaining records in the block are unrelated to alectinib and span diverse categories including naloxone and drug deactivation systems (Seminole County), emergency medical supplies and vending systems (Tucson), forensic drug reference standards (Pinellas County), employee wellness clinic services (Collier County), peer support services (San Mateo County), engineering services (Orange County), and cooperative pharmaceutical purchasing (Minnesota). None of these solicitations involve alectinib procurement.

The code appears dormant at the state and local level. Alectinib—a tyrosine kinase inhibitor indicated for anaplastic lymphoma kinase-positive non-small-cell lung cancer—is a specialty pharmaceutical requiring manufacturer direct-to-payer or institutional contracting rather than open competitive procurement by public jurisdictions. State and local procurement offices do not typically solicit branded oncologic agents through RFP, RFQ, IFB, or ITQ. If state Medicaid programs, county health systems, or hospital authorities do source alectinib, they route those purchases through group purchasing organizations, state formulary committees, or direct manufacturer agreements rather than published procurement notices. The taxonomy classification does not reflect current public-sector buying practice for this product.